Catalyst Biosciences (CBIO) PT Set at $49.00 by B. Riley

Catalyst Biosciences (NASDAQ:CBIO) has been given a $49.00 price objective by equities research analysts at B. Riley in a report issued on Friday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. B. Riley’s price target would indicate a potential upside of 52.41% from the stock’s previous close.

Other equities research analysts also recently issued research reports about the company. Zacks Investment Research upgraded Catalyst Biosciences from a “hold” rating to a “buy” rating and set a $5.25 price target on the stock in a report on Wednesday, November 8th. Chardan Capital upped their price target on Catalyst Biosciences from $10.00 to $75.00 and gave the stock a “buy” rating in a report on Friday. Finally, ValuEngine upgraded Catalyst Biosciences from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $30.00.

Shares of Catalyst Biosciences (NASDAQ:CBIO) opened at $32.15 on Friday. Catalyst Biosciences has a 1-year low of $3.11 and a 1-year high of $33.81. The firm has a market capitalization of $186.91, a PE ratio of -2.45 and a beta of 2.68.

A number of hedge funds and other institutional investors have recently modified their holdings of CBIO. Virtu KCG Holdings LLC purchased a new stake in Catalyst Biosciences during the 2nd quarter worth about $103,000. Bank of New York Mellon Corp purchased a new stake in Catalyst Biosciences during the 2nd quarter worth about $107,000. Vanguard Group Inc. increased its holdings in shares of Catalyst Biosciences by 294.1% in the 2nd quarter. Vanguard Group Inc. now owns 43,714 shares of the biopharmaceutical company’s stock valued at $204,000 after acquiring an additional 32,621 shares during the last quarter. Finally, Dimensional Fund Advisors LP purchased a new position in shares of Catalyst Biosciences in the 2nd quarter valued at about $372,000. Institutional investors own 22.90% of the company’s stock.

WARNING: “Catalyst Biosciences (CBIO) PT Set at $49.00 by B. Riley” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this news story on another website, it was stolen and republished in violation of US & international copyright & trademark laws. The correct version of this news story can be accessed at

About Catalyst Biosciences

Catalyst Biosciences, Inc, formerly Targacept, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness.

Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with's FREE daily email newsletter.

Leave a Reply